507MO REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients

• DOI: 10.1016/j.annonc.2023.09.1701
• Publication Date: 2023-10-20T12:16:44Z
• Authors: G. Lombardi; I. Desideri; V. Villani; M. Simonelli; M. Buglione; S. Chiesa; E. Franceschi; P. Gaviani; I. Stasi; C. Caserta; S. Brugnara; I.R. Lolli; E. Bennicelli; P. Bini; A. Cuccu; S. scoccianti; G. Magni; M. Caccese; G. De Salvo; V. Zagonel
• Keywords: Regorafenib; Clinical endpoint; First line treatment; Discontinuation